These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prognostic value of exhaled microsatellite alterations at 3p in NSCLC patients. Carpagnano GE; Spanevello A; Carpagnano F; Palladino GP; Prato R; Martinelli D; Digioia G; Foschino-Barbaro MP Lung Cancer; 2009 Jun; 64(3):334-40. PubMed ID: 18995925 [TBL] [Abstract][Full Text] [Related]
3. 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer. Carpagnano GE; Foschino-Barbaro MP; Spanevello A; Resta O; Carpagnano F; Mulé G; Pinto R; Tommasi S; Paradiso A Am J Respir Crit Care Med; 2008 Feb; 177(3):337-41. PubMed ID: 17962633 [TBL] [Abstract][Full Text] [Related]
4. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Carpagnano GE; Foschino-Barbaro MP; Mulé G; Resta O; Tommasi S; Mangia A; Carpagnano F; Stea G; Susca A; Di Gioia G; De Lena M; Paradiso A Am J Respir Crit Care Med; 2005 Sep; 172(6):738-44. PubMed ID: 15947287 [TBL] [Abstract][Full Text] [Related]
5. Exhaled HPV infection in lung cancer: role of MA at 3p. Carpagnano GE; Lacedonia D; Crisetti E; Palladino GP; Saliani V; Zoppo LD; Antonetti R; Natalicchio I; Foschino-Barbaro MP Arch Med Res; 2014 Jul; 45(5):383-7. PubMed ID: 24962429 [TBL] [Abstract][Full Text] [Related]
6. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544 [TBL] [Abstract][Full Text] [Related]
7. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer]. Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926 [TBL] [Abstract][Full Text] [Related]
8. Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes? Carpagnano GE; Lacedonia D; Palladino GP; Koutelou A; Martinelli D; Orlando S; Foschino-Barbaro MP Eur J Clin Invest; 2012 May; 42(5):478-86. PubMed ID: 21955247 [TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Zhou X; Kemp BL; Khuri FR; Liu D; Lee JJ; Wu W; Hong WK; Mao L Clin Cancer Res; 2000 Feb; 6(2):559-65. PubMed ID: 10690539 [TBL] [Abstract][Full Text] [Related]
10. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Felip E; Rosell R Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733 [TBL] [Abstract][Full Text] [Related]
11. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986 [TBL] [Abstract][Full Text] [Related]
12. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214 [TBL] [Abstract][Full Text] [Related]
13. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488 [TBL] [Abstract][Full Text] [Related]
14. Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer. Zhang Z; Xu F; Wang S; Li N; Wang C Lung Cancer; 2008 Jun; 60(3):434-40. PubMed ID: 18036699 [TBL] [Abstract][Full Text] [Related]
15. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L Cancer Res; 1999 Oct; 59(19):4798-803. PubMed ID: 10519387 [TBL] [Abstract][Full Text] [Related]
16. Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. Grepmeier U; Dietmaier W; Merk J; Wild PJ; Obermann EC; Pfeifer M; Hofstaedter F; Hartmann A; Woenckhaus M Int J Oncol; 2005 Aug; 27(2):481-8. PubMed ID: 16010431 [TBL] [Abstract][Full Text] [Related]
17. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study. Tseng RC; Hsieh FJ; Shih CM; Hsu HS; Chen CY; Wang YC Cancer; 2009 Jul; 115(13):2939-48. PubMed ID: 19408343 [TBL] [Abstract][Full Text] [Related]
18. Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancer. Sánchez-Céspedes M; Rosell R; Pifarré A; López-Cabrerizo MP; Barnadas A; Sánchez JJ; Lorenzo JC; Abad A; Monzó M; Navas-Palacios JJ Clin Cancer Res; 1997 Jul; 3(7):1229-35. PubMed ID: 9815804 [TBL] [Abstract][Full Text] [Related]
19. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Hirao T; Nelson HH; Ashok TD; Wain JC; Mark EJ; Christiani DC; Wiencke JK; Kelsey KT Cancer Res; 2001 Jan; 61(2):612-5. PubMed ID: 11212258 [TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]